Sponsored by:
Vcaps® Enteric Capsules
Vcaps® Enteric Capsules is a capsule technology that simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing.
Vcaps® Enteric Capsules is a capsule technology that simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing. The pharmaceutical grades of cellulosic derivatives used in Vcaps® Enteric capsules have extensive market precedence for use in providing enteric protection. Vcaps® Enteric capsules have been evaluated in-vitro and in-vivo across a number of compounds, which has proven full compliance with relevant European, Japanese and US Pharmacopeia monographs.
Vcaps® Enteric Capsules have a number of potential applications in terms of functionality, use in product development tools, and as branding and intellectual property considerations.
PROVEN FUNCTIONALITY
- Improving tolerability of API’s that cause gastric-irritation
- API protection against degradation in the gastric environment (formulation-dependent, typically APIs with low-to-moderate acid sensitivity)
- Achieving delayed or targeted release in the small intestine
A UNIQUE TECHNOLOGY
As a proprietary technology – and a viable alternative to enteric coating in the pharmaceutical industry – our intrinsically enteric capsule technologies offer potential product differentiation, life cycle management, and intellectual property opportunities.
TOOL FOR RAPID PRODUCT DEVELOPMENT
Vcaps® Enteric capsules can be utilized to greatly simplify and accelerate prototype development and rapid in-vivo testing of products requiring targeted delivery to the upper GI tract:
- Eliminate coating system preparation and application steps
- Rapid screening and optimization of enteric performance
- Remove dependency of enteric functionality with process variability
- Obviate need for process development of the enteric coating step, process scale-up and validation
By removing the need for enteric coating, intrinsically enteric capsule technologies also offer tremendous potential in early-stage product development, and can be utilized to greatly simplify formulation and process development, as well as scale-up and validation. Independent analysis has indicated that more than nine months of savings in Phase III readiness may be achievable by eliminating development, scale-up and validation steps associated with enteric coating (H2 Pharma Consulting, 2014).
Product Description
- Two-piece hard capsule
- Manufactured with pharmaceutical-grade cellulosic derivatives (HPMCAS, HPMC)
- Size #0, white opaque standard (other sizes and colors available upon request)
Regulatory Status
- Contains commercial polymers used in coating and other pharmaceutical applications for more than 20 years.
- Complies with relevant European, Japanese and US Pharmacopeia monographs
Water content – less than 6%
- Storage recommendations: 15–25ºC & 35–65%RH, in moisture-tight packaging.
- Robust performance over time and ICH conditions.
